Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (> 65 years of age) and
this population is expected to increase in the following years. A simplified geriatric …

Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic
hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor-(CAR-) T cell …

Background Age is a major risk factor for the acute and chronic complications of cancer
chemotherapy. The current approach to the prevention of these complications is reactive …

Simple Summary The treatment choice for an older patient with diffuse large B-cell
lymphoma (DLBCL) is challenging due to the complexity of the patient. Among the several …

Introduction The prognosis of diffuse large B‐cell lymphoma (DLBCL) patients with refractory
or multiply relapsed (R/R) disease is disappointing. Pixantrone is currently approved as third …

Geriatric assessment can aid in optimizing treatment strategies and supportive interventions
for older patients with diffuse large B‐cell lymphoma (DLBCL). Fondazione Italiana Linformi …

Older patients with aggressive lymphoma are extremely heterogeneous due to the high
frequency of functional limitations and comorbidities and to the different biological profiles …

Morbidity and mortality during chemotherapy in older adults with haematological malignancy
can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to …

Most patients with diffuse large B-cell lymphoma (DLBCL) are> 65 years of age, with the
number of patients expected to increase in the coming years. A comprehensive geriatric …

Abstract Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL)
include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced …